Van Hulzen Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.97M | Buy |
45,864
+417
| +0.9% | +$92.5K | 0.74% | 38 |
|
|
2025
Q4 | $10.4M | Buy |
45,447
+895
| +2% | +$204K | 0.76% | 41 |
|
|
2025
Q3 | $10.3M | Buy |
44,552
+558
| +1% | +$114K | 0.77% | 39 |
|
|
2025
Q2 | $8.17M | Buy |
43,994
+1,216
| +3% | +$226K | 0.68% | 42 |
|
|
2025
Q1 | $8.96M | Sell |
42,778
-126,596
| -75% | -$24.6M | 0.82% | 40 |
|
|
2024
Q4 | $30.1M | Buy |
169,374
+2,974
| +2% | +$547K | 2.2% | 5 |
|
|
2024
Q3 | $32.9M | Sell |
166,400
-39,234
| -19% | -$7.32M | 2.38% | 6 |
|
|
2024
Q2 | $35.3M | Buy |
205,634
+12,788
| +7% | +$2.12M | 2.37% | 6 |
|
|
2024
Q1 | $35.1M | Sell |
192,846
-3,483
| -2% | -$600K | 2.32% | 5 |
|
|
2023
Q4 | $30.4M | Sell |
196,329
-4,534
| -2% | -$661K | 2.14% | 6 |
|
|
2023
Q3 | $29.9M | Sell |
200,863
-284
| -0.1% | -$41.7K | 2.3% | 6 |
|
|
2023
Q2 | $27.1M | Buy |
201,147
+3,882
| +2% | +$569K | 2.31% | 9 |
|
|
2023
Q1 | $31.4M | Buy |
197,265
+40,954
| +26% | +$6.26M | 2.95% | 3 |
|
|
2022
Q4 | $25.2M | Buy |
156,311
+8,357
| +6% | +$1.28M | 2.91% | 3 |
|
|
2022
Q3 | $19.9M | Sell |
147,954
-27,565
| -16% | -$3.96M | 2.45% | 5 |
|
|
2022
Q2 | $26.9M | Sell |
175,519
-13,052
| -7% | -$1.99M | 3.21% | 4 |
|
|
2022
Q1 | $30.6M | Buy |
188,571
+3,668
| +2% | +$533K | 3.24% | 3 |
|
|
2021
Q4 | $25.1M | Buy |
184,903
+72,784
| +65% | +$8.6M | 2.74% | 5 |
|
|
2021
Q3 | $12.1M | Buy |
112,119
+447
| +0.4% | +$51.1K | 1.8% | 15 |
|
|
2021
Q2 | $12.6M | Buy |
111,672
+4,192
| +4% | +$472K | 1.89% | 13 |
|
|
2021
Q1 | $11.6M | Sell |
107,480
-6,126
| -5% | -$655K | 1.86% | 11 |
|
|
2020
Q4 | $12.2M | Sell |
113,606
-7,013
| -6% | -$674K | 1.84% | 11 |
|
|
2020
Q3 | $10.6M | Sell |
120,619
-9,553
| -7% | -$899K | 1.59% | 17 |
|
|
2020
Q2 | $12.8M | Sell |
130,172
-10,803
| -8% | -$951K | 1.92% | 11 |
|
|
2020
Q1 | $10.7M | Buy |
140,975
+5,469
| +4% | +$466K | 2.31% | 10 |
|
|
2019
Q4 | $12M | Sell |
135,506
-10,101
| -7% | -$839K | 2.32% | 5 |
|
|
2019
Q3 | $11M | Buy |
145,607
+30,551
| +27% | +$2.09M | 2.33% | 4 |
|
|
2019
Q2 | $8.37M | Buy |
115,056
+83,703
| +267% | +$6.58M | 1.83% | 14 |
|
|
2019
Q1 | $2.53M | Sell |
31,353
-7,096
| -18% | -$581K | 0.68% | 37 |
|
|
2018
Q4 | $3.54M | Buy |
38,449
+5,076
| +15% | +$446K | 1.03% | 31 |
|
|
2018
Q3 | $3.16M | Buy |
33,373
+3,986
| +14% | +$378K | 0.84% | 39 |
|
|
2018
Q2 | $2.72M | Buy |
29,387
+8,836
| +43% | +$863K | 0.81% | 44 |
|
|
2018
Q1 | $1.95M | Sell |
20,551
-1,065
| -5% | -$117K | 0.6% | 54 |
|
|
2017
Q4 | $2.09M | Sell |
21,616
-35,461
| -62% | -$3.34M | 0.64% | 51 |
|
|
2017
Q3 | $5.07M | Sell |
57,077
-11,090
| -16% | -$844K | 1.71% | 18 |
|
|
2017
Q2 | $4.94M | Buy |
68,167
+7,686
| +13% | +$517K | 1.96% | 13 |
|
|
2017
Q1 | $3.94M | Buy |
60,481
+4,499
| +8% | +$283K | 1.8% | 15 |
|
|
2016
Q4 | $3.51M | Buy |
55,982
+290
| +0.5% | +$17.7K | 1.63% | 14 |
|
|
2016
Q3 | $3.51M | Buy |
55,692
+4,678
| +9% | +$303K | 1.91% | 12 |
|
|
2016
Q2 | $3.16M | Buy |
51,014
+1,132
| +2% | +$69K | 1.8% | 14 |
|
|
2016
Q1 | $2.85M | Buy |
49,882
+21,073
| +73% | +$1.17M | 1.62% | 18 |
|
|
2015
Q4 | $1.71M | Buy |
28,809
+8,643
| +43% | +$498K | 1.06% | 36 |
|
|
2015
Q3 | $1.1M | Sell |
20,166
-38,573
| -66% | -$2.51M | 0.71% | 42 |
|
|
2015
Q2 | $3.95M | Buy |
58,739
+2,633
| +5% | +$172K | 2.13% | 10 |
|
|
2015
Q1 | $3.28M | Buy |
56,106
+1,833
| +3% | +$111K | 2.01% | 11 |
|
|
2014
Q4 | $3.55M | Buy |
+54,273
| New | +$3.42M | 2.46% | 11 |
|
|
2014
Q1 | – | Sell |
-19,951
| Closed | -$1.05M | – | 85 |
|
|
2013
Q4 | $1.05M | Buy |
+19,951
| New | +$981K | 0.91% | 40 |
|
Other funds holding ABBV
VCM
VPM
Van Hulzen Asset Management's ABBV Position: Q1 2026 in Review
Van Hulzen Asset Management increased its AbbVie (ABBV) stake by 0.92% in Q1 2026, buying an estimated $92.5K and bringing the position to 45,864 shares worth $9.97M. The position accounts for 0.74% of the portfolio, ranked #38.
Van Hulzen Asset Management first reported a position in ABBV in Q4 2013 and has held it in 47 quarters since. The position peaked at $35.3M in Q2 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Van Hulzen Asset Management held 45,864 shares of AbbVie worth $9.97M as of Q1 2026.
- Van Hulzen Asset Management bought 417 AbbVie shares in Q1 2026, an estimated $92.5K.
- AbbVie made up 0.74% of Van Hulzen Asset Management's portfolio in Q1 2026, its #38 holding.
- Van Hulzen Asset Management first reported a position in AbbVie in Q4 2013 and has held it in 47 quarters since.
- Van Hulzen Asset Management's AbbVie position peaked at $35.3M in Q2 2024.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Van Hulzen Asset Management's 13F filing for Q1 2026, filed 14 May 2026.